![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Efficacy and Safety of Bulevirtide 2 mg or 10 mg for 96 Weeks in Chronic Hepatitis Delta, Including in 2 Patients With HIV/Hepatitis B Virus/Hepatitis Delta Virus
|
|
|
CROI 2024 March 3-6 Denver
Heiner Wedemeyer1, Soo Aleman2, Maurizia Brunetto3,4, David L Wyles5, Viacheslav Morozov6, Vladimir Chulanov7, Ben L Da8, Renee-Claude Mercier8, Grace M Chee8, Mingyang Li8, Pietro Lampertico9,10
![0327241](../images/032724/032724-28/0327241.gif)
![0327242](../images/032724/032724-28/0327242.gif)
![0327243](../images/032724/032724-28/0327243.gif)
![0327244](../images/032724/032724-28/0327244.gif)
![0327245](../images/032724/032724-28/0327245.gif)
![0327246](../images/032724/032724-28/0327246.gif)
![0327247](../images/032724/032724-28/0327247.gif)
![0327248](../images/032724/032724-28/0327248.gif)
![0327249](../images/032724/032724-28/0327249.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|